SuperworthAnaptysbio EPS ANAB
Diluted earnings per share by quarter and over the last twelve months, from 2016.
- Last 12 months, to Jun 30, 2026
- $4.57
- Latest quarter, Q4 FY26
- $4.87
- +308% on a year earlier
- Fiscal year 2026
- $4.57
Anaptysbio's earnings per share was $4.57 over the twelve months to Jun 30, 2026.
In its latest quarter, Q4 FY26, it was $4.87, up 308% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | $4.57 | n/a |
| FY2025 | −$0.21 | n/a |
| FY2024 | −$3.47 | n/a |
| FY2023 | −$4.05 | n/a |
| FY2022 | −$3.05 | n/a |
| FY2021 | −$1.40 | n/a |
| FY2020 | −$0.49 | n/a |
| FY2019 | −$2.41 | n/a |
| FY2018 | −$1.66 | n/a |
| FY2017 | −$1.09 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | $4.87 | +308% | $4.57 | |
| Q2 FY26 | −$1.84 | n/a | −$1.19 | |
| Q4 FY25 | $1.19 | n/a | −$0.21 | |
| Q3 FY25 | $0.35 | n/a | −$1.88 | |
| Q2 FY25 | −$0.89 | n/a | −$2.99 | |
| Q1 FY25 | −$0.85 | n/a | −$3.23 | |
| Q4 FY24 | −$0.48 | n/a | −$3.47 | |
| Q3 FY24 | −$0.76 | n/a | −$4.05 | |
| Q2 FY24 | −$1.14 | n/a | −$4.23 | |
| Q1 FY24 | −$1.09 | n/a | −$4.09 | |
| Q4 FY23 | −$1.06 | n/a | −$4.05 | |
| Q3 FY23 | −$0.94 | n/a | −$3.61 |
Against its peers
Companies in Drug Manufacturers - General nearest Anaptysbio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ABUSArbutus Biopharma | $0.78 | |
| NRIXNurix Therapeutics | $2.31 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $2.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Anaptysbio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.